Today: 22 March 2026
Subscribe
Browse Category

Stock Market 12 January 2026

Marvell stock stalls even as chip ETFs rise — what’s moving MRVL now

Marvell stock stalls even as chip ETFs rise — what’s moving MRVL now

Marvell Technology shares slipped to $83.21 Monday afternoon, lagging a broader chip rally as the iShares Semiconductor ETF rose 0.7% and Broadcom gained 2.5%. Traders are watching Tuesday’s U.S. CPI data and Thursday’s Taiwan Semiconductor earnings for signals on AI demand. Marvell’s next earnings report is expected in early March. The company recently agreed to buy XConn Technologies for about $540 million.
12 January 2026
··
CrowdStrike stock slips on KeyBanc downgrade as 2026 security budget doubts surface

CrowdStrike stock slips on KeyBanc downgrade as 2026 security budget doubts surface

CrowdStrike shares fell 0.6% to $467.84 Monday after KeyBanc downgraded the stock to “Sector Weight,” citing high valuation and uncertain AI-driven security spending in 2026. The company announced a new partnership with Nord Security targeting small and midsize businesses. KeyBanc’s CIO survey suggests security budgets will trail overall IT spending next year. Other software stocks like Okta rose on the news.
12 January 2026
··
Dave Inc stock drops nearly 9% as fintech lenders slide; CPI test looms for DAVE

Dave Inc stock drops nearly 9% as fintech lenders slide; CPI test looms for DAVE

Dave Inc (DAVE.O) shares fell 8.8% to $218.29 Monday after President Trump called for a 10% cap on credit card interest rates, sparking a selloff in credit-sensitive stocks. About 1.1 million Dave shares traded by mid-afternoon. The drop mirrored declines in other fintechs, including Upstart and Affirm. Dave also faces a Justice Department complaint alleging it misled users about fees, which the company disputes.
12 January 2026
··
Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

Arcutis Biotherapeutics shares fell 8.7% to $25.76 Monday after the company set a 2026 net product sales target of $455–$470 million for its ZORYVE franchise. The company reported $99.2 million in net product revenue last quarter and ended September with $191.4 million in cash. Arcutis plans to expand its sales team by 20% and expects key clinical trial data in early 2026. The stock hit a session low of $25.51.
12 January 2026
··
Caris Life Sciences (CAI) stock drops on preliminary 2025 results, Everlywell cancer-screening deal

Caris Life Sciences (CAI) stock drops on preliminary 2025 results, Everlywell cancer-screening deal

Caris Life Sciences shares fell 8.5% to $26.08 in afternoon trading after the company reported preliminary 2025 revenue near $800 million, up 94%, but warned of significant prior-period adjustments. The company also announced a partnership with Everlywell to develop a blood-based early cancer detection test, with more details expected at the JPMorgan Healthcare Conference later Monday.
12 January 2026
··
HealthEquity stock slides nearly 10% after 2027 outlook; JPM conference is next test

HealthEquity stock slides nearly 10% after 2027 outlook; JPM conference is next test

HealthEquity shares fell about 10% Monday after the company issued a cautious initial fiscal 2027 outlook, projecting revenue between $1.38 billion and $1.41 billion and an HSA cash yield near 3.75%. The stock last traded at $84.62, down $9.53. Executives will present at the J.P. Morgan Healthcare Conference on Tuesday. The company reaffirmed its 2026 guidance.
12 January 2026
··
Credo Technology (CRDO) stock climbs as AI-chip trade stays hot; Needham conference next

Credo Technology (CRDO) stock climbs as AI-chip trade stays hot; Needham conference next

Credo Technology shares rose 3.1% to $155.10 Monday, trading as high as $156.43 amid sector gains and anticipation of its Jan. 14 presentation at Needham’s Growth Conference. The company last reported $268 million in quarterly revenue and forecast up to $345 million for the next period. TSMC will report earnings Jan. 15, with investors watching for AI chip demand signals.
12 January 2026
···
Synchrony Financial stock slides on Trump’s 10% credit-card rate cap pitch — what investors watch next

Synchrony Financial stock slides on Trump’s 10% credit-card rate cap pitch — what investors watch next

Synchrony shares fell 8.2% to $79.76 after Donald Trump called for a one-year 10% cap on credit card interest rates, sparking fears of tighter regulation and profit declines. Analysts said such a cap would require congressional approval. Bread Financial, Capital One, and Barclays also saw declines. Separately, Synchrony expanded CareCredit integration with Fiserv’s Clover platform, now reaching over 40,000 providers.
12 January 2026
·
Texas Instruments stock slips as chip ETF firms; investors eye Jan. 27 earnings amid Fed jitters

Texas Instruments stock slips as chip ETF firms; investors eye Jan. 27 earnings amid Fed jitters

Texas Instruments shares slipped 0.2% to $189.85 in Monday afternoon trading, underperforming chip sector peers as the iShares Semiconductor ETF rose 0.7% and Nvidia gained about 1%. Investors are watching TI’s Jan. 27 earnings for signals on industrial and auto demand amid market volatility tied to a Justice Department probe involving Fed Chair Jerome Powell.
12 January 2026
····
Figure Technology Solutions stock drops nearly 10% after FIGR posts preliminary Q4 loan data

Figure Technology Solutions stock drops nearly 10% after FIGR posts preliminary Q4 loan data

Figure Technology Solutions shares fell 9.6% to $52.50 Monday after releasing preliminary Q4 metrics. The company reported $2.705 billion in Q4 consumer loan marketplace volume, up 131% from a year earlier, and $328 million in $YLDS stablecoin circulation. Investors are watching for Tuesday’s U.S. CPI report and the Fed’s January meeting for rate signals.
12 January 2026
··
Bread Financial (BFH) stock slides on Trump’s 10% credit-card rate cap push; what’s next

Bread Financial (BFH) stock slides on Trump’s 10% credit-card rate cap push; what’s next

Bread Financial shares fell 10.8% to $71.65 Monday after Donald Trump proposed a one-year 10% cap on credit card interest rates, with no details on enforcement. The selloff spread to other lenders, including Synchrony and Capital One. Analysts questioned the proposal’s viability, citing legal hurdles. Bread Financial reports earnings Jan. 29, with investors watching for commentary on policy risks.
12 January 2026
·····
Lululemon stock rises after holiday-quarter outlook shifts to high end as LULU investors eye ICR

Lululemon stock rises after holiday-quarter outlook shifts to high end as LULU investors eye ICR

Lululemon shares rose 3.2% to $210.43 Monday after the company said holiday-quarter revenue and profit would reach the high end of its forecast, citing strong seasonal demand. The retailer maintained its margin and expense outlook. CEO Calvin McDonald steps down Jan. 31, with interim co-CEOs named as the board searches for a replacement. Founder Chip Wilson has launched a proxy fight as Elliott Management builds a $1 billion stake.
12 January 2026
··
GeneDx (WGS) stock dives on 2026 guidance despite strong 2025 prelims — what to watch next

GeneDx (WGS) stock dives on 2026 guidance despite strong 2025 prelims — what to watch next

GeneDx shares fell about 14% to $115.75 Monday after releasing preliminary 2025 results and 2026 revenue guidance above analyst estimates. The company projected 2026 revenue of $540–$555 million and positive adjusted net income. Investors are awaiting CEO remarks at the Jan. 14 J.P. Morgan Healthcare Conference and the Feb. 23 earnings report for further details. The latest figures remain unaudited and subject to revision.
12 January 2026
·
Honeywell stock flat as new Google Cloud retail tech lands, Citi trims target ahead of earnings

Honeywell stock flat as new Google Cloud retail tech lands, Citi trims target ahead of earnings

Honeywell shares edged up 0.1% to $207.50 after launching new software tools for retail and warehouse operations. Citi lowered its price target to $262 but maintained a buy rating. Investors await Honeywell’s Jan. 29 results and 2026 outlook for signs of demand and margin trends. Honeywell will start rolling out its new Smart Shopping Platform in February.
12 January 2026
··
D.R. Horton stock rises as KBW trims target — what Wall Street is watching next

D.R. Horton stock rises as KBW trims target — what Wall Street is watching next

D.R. Horton shares rose about 1% to $158.82 Monday afternoon, tracking gains in other major homebuilders. Keefe Bruyette & Woods cut its price target on the stock to $168 from $175 but kept a “Market Perform” rating. Investors are focused on D.R. Horton’s Jan. 20 earnings after the company warned that affordability pressures could keep sales incentives high in 2026.
12 January 2026
·····
SoFi stock slides as CEO Anthony Noto weighs Trump’s 10% credit-card rate cap

SoFi stock slides as CEO Anthony Noto weighs Trump’s 10% credit-card rate cap

SoFi Technologies shares fell 2.4% to $26.74 Monday after CEO Anthony Noto said Trump’s proposed 10% cap on credit-card rates could boost demand for personal loans. The stock had reached $28.05 before reversing. Capital One and Synchrony dropped 7.5% and 8.9%, while Visa and Mastercard each lost about 2%. Trump’s plan would cap rates for one year starting January 20.
12 January 2026
··
Nike stock dips even after Jefferies’ “buy aggressively” call — what NKE investors are watching next

Nike stock dips even after Jefferies’ “buy aggressively” call — what NKE investors are watching next

Nike shares fell 0.6% to $65.52 Monday afternoon, underperforming the broader market despite Jefferies reaffirming its buy rating and $110 price target ahead of the ICR conference. Nike’s latest quarter showed revenue up 1% to $12.4 billion, but net income dropped 32% and gross margin fell to 40.6% due to higher tariffs. Wholesale revenue rose, while direct and Converse sales declined.
12 January 2026
··
Lemonade stock hits fresh 52-week high as LMND rallies; traders watch short interest and earnings

Lemonade stock hits fresh 52-week high as LMND rallies; traders watch short interest and earnings

Lemonade shares jumped 7.7% to $85.81 Monday, hitting a new 52-week high amid heavy short interest and volatile trading. About 20% of the float was shorted as of mid-December, raising the risk of sharp moves. Chief insurance officer John Peters sold 10,000 shares Jan. 6 at $80 under a pre-set plan. The next earnings report is expected Feb. 24.
12 January 2026
··
1 … 529 530 531 532 533 … 1,358

Stock Market Today

  • Globant (GLOB) Faces 66% Share Slide: Undervalued Opportunity or Value Trap?
    March 21, 2026, 11:13 PM EDT. Globant's shares have dropped 65.8% in the past year, trading at $44.71. Despite this slump, a Discounted Cash Flow (DCF) analysis values the stock at $98.09, implying a 54.4% undervaluation. The DCF model forecasts rising free cash flow, projecting $309 million by 2030. However, the company's price-to-earnings (P/E) ratio, a metric comparing stock price to earnings, reflects market skepticism amid sector-wide reassessments of growth and risk in software and IT services. Globant holds a valuation score of 4 out of 6, indicating mixed signals on its true value. Investors watch sector shifts closely as sentiment, interest rates, and risk appetite shape valuations for tech firms like Globant.
Go toTop